Efficacy and Safety of rhEGF in Diabetic Foot Ulcer Patients With Uncontrolled Diabetic Mellitus

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2012 by Daewoong Pharmaceutical Co. LTD..
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by (Responsible Party):
Daewoong Pharmaceutical Co. LTD.
ClinicalTrials.gov Identifier:
NCT01629199
First received: June 25, 2012
Last updated: July 12, 2012
Last verified: July 2012

June 25, 2012
July 12, 2012
October 2010
September 2012   (final data collection date for primary outcome measure)
At 12 weeks, wound closure rate of diabetic foot ulcers
Same as current
Complete list of historical versions of study NCT01629199 on ClinicalTrials.gov Archive Site
  • Time to reach complete wound closure
  • At 12 weeks, average size reduction of diabetic ulcer
  • Time to reach complete wound closure
  • At 12 weeks, average size ruduction of diabetic ulcer
  • At 12 weeks, average size rudction ratio of diabetic ulcer
  • The time to ruduce ulcer size, 1㎠
Not Provided
Not Provided
 
Efficacy and Safety of rhEGF in Diabetic Foot Ulcer Patients With Uncontrolled Diabetic Mellitus
The Clinical Trial for Evaluation of Efficacy and Safety of rhEGF(Recombinant Human Epidermal Growth Factor) in Diabetic Foot Ulcer Patients With Uncontrolled Diabetes Mellitus.

The purpose of this clinical trial is to evaluate the safety and efficacy of rhEGF (recombinant human Epidermal Growth Factor) in diabetic foot ulcer patients with uncontrolled diabetes mellitus.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Diabetic Foot Ulcer Patients With Uncontrolled Diabetes Mellitus
  • Drug: rhEGF(recombinant human Epidermal Growth Factor)
  • Drug: placebo of rhEGF(recombinant human Epidermal Growth Factor)
  • Experimental: EGF
    rhEGF(recombinant human Epidermal Growth Factor)
    Intervention: Drug: rhEGF(recombinant human Epidermal Growth Factor)
  • Placebo Comparator: placebo
    Intervention: Drug: placebo of rhEGF(recombinant human Epidermal Growth Factor)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
176
Not Provided
September 2012   (final data collection date for primary outcome measure)
Not Provided
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
NCT01629199
DW-EGF011P
Not Provided
Daewoong Pharmaceutical Co. LTD.
Daewoong Pharmaceutical Co. LTD.
Not Provided
Not Provided
Daewoong Pharmaceutical Co. LTD.
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP